Commonwealth Equity Services’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $291K | Buy |
196,797
+146,772
| +293% | +$217K | ﹤0.01% | 3609 |
|
|
2025
Q1 | $128K | Buy |
50,025
+25
| +0.1% | +$64 | ﹤0.01% | 3949 |
|
|
2024
Q4 | $94K | Hold |
50,000
| – | – | ﹤0.01% | 3918 |
|
|
2024
Q3 | $51K | Sell |
50,000
-100
| -0.2% | -$102 | ﹤0.01% | 3935 |
|
|
2024
Q2 | $59K | Hold |
50,100
| – | – | ﹤0.01% | 3876 |
|
|
2024
Q1 | $63K | Hold |
50,100
| – | – | ﹤0.01% | 3862 |
|
|
2023
Q4 | $89K | Hold |
50,100
| – | – | ﹤0.01% | 3689 |
|
|
2023
Q3 | $83K | Sell |
50,100
-100
| -0.2% | -$166 | ﹤0.01% | 3595 |
|
|
2023
Q2 | $100K | Buy |
50,200
+100
| +0.2% | +$199 | ﹤0.01% | 3571 |
|
|
2023
Q1 | $105 | Hold |
50,100
| – | – | ﹤0.01% | 3489 |
|
|
2022
Q4 | $68K | Buy |
+50,100
| New | +$68K | ﹤0.01% | 3474 |
|
|
2022
Q1 | – | Sell |
-40,290
| Closed | -$33K | – | 3781 |
|
|
2021
Q4 | $33K | Buy |
+40,290
| New | +$33K | ﹤0.01% | 3571 |
|
|
2017
Q2 | – | Sell |
-3,775
| Closed | -$51K | – | 2546 |
|
|
2017
Q1 | $51K | Buy |
+3,775
| New | +$51K | ﹤0.01% | 2325 |
|